In this video, David Williamson reviews Johnson & Johnson's latest earnings report. The over-the-counter and nutritional business both grew, as did the pharma division, with a blood thinner holding its own and a new diabetes drug that looks promising. Medical devices saw a 10% uptick, but that was considered a disappointment in light of recent acquisitions.
David says he's neutral on the stock, but he also notes its 2.9% dividend and thinks it could prove to be a safe long-term investment. Check out the video for more details.